Latest papers

Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study.

Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors.

Urticarial hypersensitivity reaction caused by temozolomide.

Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.

Manipulating tumor acidification as a cancer treatment strategy.

Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.

3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy.

Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer.

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.

Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.

Progress in treating multiple myeloma. Thanks to a host of effective new therapies, patients are enjoying years in remission from this malignant blood cancer.

Commentary.

Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.

Commentary.

Which dose of busulfan is best?

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.

Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.

Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.

Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels.

Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.